Evolus $EOLS Consolidation Before Next Move Higher

EOLS stock is consolidating as of April 26, 2022, as it seems to be prepared to take the next leg higher.

Evolus to Report First Quarter 2022 Results and Provide Business Update

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced that it will report its first quarter 2022 financial results and provide a business update on Tuesday, May 10, 2022, after the U.S. financial markets close.

Evolus Announces First Patient Enrolled in Phase II Clinical Study Evaluating “Extra-Strength” Dose of Jeuveau®

On March 31, 2022, Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, has enrolled its first patient in a clinical study evaluating an “extra-strength” dose for extended duration of Jeuveau® (prabotulinumtoxinA-xvfs), its flagship neurotoxin product and the first and only neurotoxin dedicated exclusively to aesthetics.

The “Extra-Strength” Glabellar Line Study is a multicenter, double blind, randomized trial that will follow 150 patients for up to 12 months. The study will include two active controls—the currently approved 20 units of Jeuveau® and 20 units of BOTOX® Cosmetic—which will be compared to 40 units of “extra-strength” Jeuveau®. Five study sites have been selected to participate. Evolus anticipates completing the study in the first half of 2023.

“Enrolling the first patient in the ‘extra-strength’ trial marks an important milestone for Evolus—we are now one step closer to the possibility of fulfilling an unmet need in the aesthetic neurotoxin segment,” said David Moatazedi, President and CEO, Evolus. “While many of our customers believe the original strength, 20-unit dose of Jeuveau® will comprise a majority of their use, clinicians have voiced the desire for an ‘extra-strength’ dose option as well. As a cash pay, aesthetics-only company, Evolus is uniquely positioned to capitalize on this opportunity and meet the needs of our customers.”

Jeuveau® is used for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines) in adults below 65 years of age. The largest head-to-head pivotal study versus BOTOX® to date evaluated the safety and efficacy of Jeuveau®, enrolling more than 2,100 patients as part of Evolus’ TRANSPARENCY clinical development program. The product is approved for sale in the United States under the brand name Jeuveau® and in Canada under the brand name Nuceiva®. The company plans to launch Nuceiva® in Europe in the second half of 2022.

📺 Behind the Bell: Evolus

Behind the Bell: Evolus

📉 EOLS Stock Chart

close

Don’t miss these catalysts!

We don’t spam! Read our privacy policy for more info.

Latest News

Sign up for our Free Daily Newsletter

Guerilla Stock Trading